Neuroglia has an essential role in pain perception that goes beyond neuropathic pain and is now considered to play a major role in the processes of sensitization, establishment of chronic pain and nociplasticity. In this intricate process of plasticity and neuroinflammation, there are multiple receptors, one of them the transient receptor potential (TRP) that has different types and subtypes in relation to their amino acids. These receptors vary in each person in relation to their sex, hormonal profile, genetics and age, which may explain the variability in pain perception. There are some treatments that intervene in these receptors and many more are in development, which could become a novel and interesting alternative therapy.
{"title":"Transient receptor potential (TRP) in neuroglia and their role in pain. Brief review","authors":"L. Arce Gálvez , J.M. Mancera Álzate , M.F. Rosero Chamorro , Á.J. Tellez Pérez , A.F. Ausenón , J.D. Cardona Bahamon , L.M. Rodriguez Vélez","doi":"10.1016/j.neurop.2025.100205","DOIUrl":"10.1016/j.neurop.2025.100205","url":null,"abstract":"<div><div>Neuroglia has an essential role in pain perception that goes beyond neuropathic pain and is now considered to play a major role in the processes of sensitization, establishment of chronic pain and nociplasticity. In this intricate process of plasticity and neuroinflammation, there are multiple receptors, one of them the transient receptor potential (TRP) that has different types and subtypes in relation to their amino acids. These receptors vary in each person in relation to their sex, hormonal profile, genetics and age, which may explain the variability in pain perception. There are some treatments that intervene in these receptors and many more are in development, which could become a novel and interesting alternative therapy.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 4","pages":"Article 100205"},"PeriodicalIF":0.0,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145018487","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100197
M.A. Hernández , B. González , Y. Contreras , L.M. Armas
Introduction
Multiple sclerosis (MS) may be associated with a range of rheumatic diseases. Rheumatoid arthritis is a chronic inflammatory disease typically affecting small- and medium-size joints. MS has been associated with antiphospholipid syndrome.
Development
The treatment of these patients must be carefully established, considering the presence of neurological symptoms or central nervous system comorbidities. Patients with MS and rheumatoid arthritis should not be treated with TNF inhibitors, as these may exacerbate the neurological symptoms. Most biological drugs may favour opportunistic infections of the central nervous system; therefore, patients developing neurological symptoms should undergo comprehensive examination, and biological treatment should be adapted according to the results.
Conclusions
We summarise the main recommendations for the treatment of patients with MS associated with rheumatic diseases.
{"title":"Multiple sclerosis and rheumatic diseases: Rheumatoid arthritis, antiphospholipid syndrome, and systemic lupus erythematosus","authors":"M.A. Hernández , B. González , Y. Contreras , L.M. Armas","doi":"10.1016/j.neurop.2025.100197","DOIUrl":"10.1016/j.neurop.2025.100197","url":null,"abstract":"<div><h3>Introduction</h3><div>Multiple sclerosis (MS) may be associated with a range of rheumatic diseases. Rheumatoid arthritis is a chronic inflammatory disease typically affecting small- and medium-size joints. MS has been associated with antiphospholipid syndrome.</div></div><div><h3>Development</h3><div>The treatment of these patients must be carefully established, considering the presence of neurological symptoms or central nervous system comorbidities. Patients with MS and rheumatoid arthritis should not be treated with TNF inhibitors, as these may exacerbate the neurological symptoms. Most biological drugs may favour opportunistic infections of the central nervous system; therefore, patients developing neurological symptoms should undergo comprehensive examination, and biological treatment should be adapted according to the results.</div></div><div><h3>Conclusions</h3><div>We summarise the main recommendations for the treatment of patients with MS associated with rheumatic diseases.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100197"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144548769","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100199
M. Dominguez-Gallego, V. Meca-Lallana, C. Ana Belén
Introduction
Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established between this condition and other autoimmune diseases, including multiple sclerosis (MS). The prevalence of MS in patients with IBD is 0.2%; the association between the 2 conditions is attributed to shared genetic and environmental pathogenic mechanisms.
Development
In patients presenting with both diseases, several considerations should be taken into account when selecting the most appropriate treatment. Regarding MS treatment, interferons have been associated with worsening of IBD symptoms, whereas such monoclonal antibodies as rituximab and ocrelizumab may cause gastrointestinal toxicity, and alemtuzumab is not recommended due to increased risk of autoimmune complications. Natalizumab and sphingosine 1-phosphate modulators, such as ozanimod, constitute safer and more effective options for patients with IBD.
Regarding treatments for IBD, TNF-α antagonists are contraindicated in patients with MS due to the associated risk of central nervous system demyelination. Vedolizumab and ustekinumab are the recommended alternatives in these cases.
Conclusions
Though weak, the association between IBD and MS should be acknowledged; preferably, management of these patients should include medications that treat both conditions simultaneously.
{"title":"Inflammatory bowel disease and multiple sclerosis","authors":"M. Dominguez-Gallego, V. Meca-Lallana, C. Ana Belén","doi":"10.1016/j.neurop.2025.100199","DOIUrl":"10.1016/j.neurop.2025.100199","url":null,"abstract":"<div><h3>Introduction</h3><div>Inflammatory bowel disease (IBD), which mainly includes Crohn’s disease and ulcerative colitis, is characterised by chronic inflammation in the gastrointestinal tract, triggered and perpetuated by an altered immune response. An association has been established between this condition and other autoimmune diseases, including multiple sclerosis (MS). The prevalence of MS in patients with IBD is 0.2%; the association between the 2 conditions is attributed to shared genetic and environmental pathogenic mechanisms.</div></div><div><h3>Development</h3><div>In patients presenting with both diseases, several considerations should be taken into account when selecting the most appropriate treatment. Regarding MS treatment, interferons have been associated with worsening of IBD symptoms, whereas such monoclonal antibodies as rituximab and ocrelizumab may cause gastrointestinal toxicity, and alemtuzumab is not recommended due to increased risk of autoimmune complications. Natalizumab and sphingosine 1-phosphate modulators, such as ozanimod, constitute safer and more effective options for patients with IBD.</div><div>Regarding treatments for IBD, TNF-α antagonists are contraindicated in patients with MS due to the associated risk of central nervous system demyelination. Vedolizumab and ustekinumab are the recommended alternatives in these cases.</div></div><div><h3>Conclusions</h3><div>Though weak, the association between IBD and MS should be acknowledged; preferably, management of these patients should include medications that treat both conditions simultaneously.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100199"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144570751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100196
S. Martínez-Yélamos , Á. Pérez-Sempere
Introduction
This study explores the association between multiple sclerosis (MS) and other autoimmune diseases, including myasthenia gravis (MG), autoimmune encephalitis (AE), and demyelinating polyneuropathies such as combined central and peripheral demyelination (CCPD), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS).
Development
For each association, we discuss epidemiological data, clinical features, and therapeutic management strategies. The prevalence of MG is higher in patients with MS than in the general population. Certain MS treatments, such as alemtuzumab, may increase the risk of developing MG or AE. Among the most suitable therapeutic options for patients with coexisting MG or AE are azathioprine and rituximab. Antibody-mediated AE associated with MS is managed similarly to AE unrelated to MS. The association between MS and CIDP contributes to neurological disability and is likely underdiagnosed.
Conclusions
The coexistence of MS with other autoimmune diseases presents significant diagnostic and therapeutic challenges. Awareness of the therapeutic options available for each association is essential in order to identify the most appropriate approach in each case. Early recognition and adequate management of these comorbidities may improve clinical outcomes and enhance patients’ quality of life.
{"title":"Other autoimmune diseases and multiple sclerosis","authors":"S. Martínez-Yélamos , Á. Pérez-Sempere","doi":"10.1016/j.neurop.2025.100196","DOIUrl":"10.1016/j.neurop.2025.100196","url":null,"abstract":"<div><h3>Introduction</h3><div>This study explores the association between multiple sclerosis (MS) and other autoimmune diseases, including myasthenia gravis (MG), autoimmune encephalitis (AE), and demyelinating polyneuropathies such as combined central and peripheral demyelination (CCPD), chronic inflammatory demyelinating polyneuropathy (CIDP), and Guillain-Barré syndrome (GBS).</div></div><div><h3>Development</h3><div>For each association, we discuss epidemiological data, clinical features, and therapeutic management strategies. The prevalence of MG is higher in patients with MS than in the general population. Certain MS treatments, such as alemtuzumab, may increase the risk of developing MG or AE. Among the most suitable therapeutic options for patients with coexisting MG or AE are azathioprine and rituximab. Antibody-mediated AE associated with MS is managed similarly to AE unrelated to MS. The association between MS and CIDP contributes to neurological disability and is likely underdiagnosed.</div></div><div><h3>Conclusions</h3><div>The coexistence of MS with other autoimmune diseases presents significant diagnostic and therapeutic challenges. Awareness of the therapeutic options available for each association is essential in order to identify the most appropriate approach in each case. Early recognition and adequate management of these comorbidities may improve clinical outcomes and enhance patients’ quality of life.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100198
M.A. Hernández , Y. Contreras , B. González , L.M. Armas
Introduction
Multiple sclerosis can be associated with a range of rheumatic processes. Behçet disease is a relapsing, multisystemic, immune-mediated chronic vasculitic disorder of unknown aetiology, whose symptoms overlap with those of many autoinflammatory processes. Sarcoidosis is a universally distributed multisystem granulomatous disease. Sjögren syndrome is a chronic, autoimmune, inflammatory disease characterised by lymphocytic infiltration in exocrine glands, which causes xerostomia (dry mouth) and xerophthalmia (dry eyes). The most frequent extraglandular manifestations of the syndrome are musculoskeletal problems.
Development
We describe the most significant neurological complications of these rheumatic diseases, as well as the pharmacological treatments that may be indicated for these conditions and the possible contraindications in patients receiving treatment for multiple sclerosis.
Conclusions
We provide a series of recommendations for the treatment of patients with multiple sclerosis who also present with Behçet disease, sarcoidosis, or Sjögren syndrome. Co-presence of any of these rheumatic diseases constitutes a contraindication for some treatments.
{"title":"Multiple sclerosis and rheumatic diseases: Behçet disease, sarcoidosis, and Sjögren syndrome","authors":"M.A. Hernández , Y. Contreras , B. González , L.M. Armas","doi":"10.1016/j.neurop.2025.100198","DOIUrl":"10.1016/j.neurop.2025.100198","url":null,"abstract":"<div><h3>Introduction</h3><div>Multiple sclerosis can be associated with a range of rheumatic processes. Behçet disease is a relapsing, multisystemic, immune-mediated chronic vasculitic disorder of unknown aetiology, whose symptoms overlap with those of many autoinflammatory processes. Sarcoidosis is a universally distributed multisystem granulomatous disease. Sjögren syndrome is a chronic, autoimmune, inflammatory disease characterised by lymphocytic infiltration in exocrine glands, which causes xerostomia (dry mouth) and xerophthalmia (dry eyes). The most frequent extraglandular manifestations of the syndrome are musculoskeletal problems.</div></div><div><h3>Development</h3><div>We describe the most significant neurological complications of these rheumatic diseases, as well as the pharmacological treatments that may be indicated for these conditions and the possible contraindications in patients receiving treatment for multiple sclerosis.</div></div><div><h3>Conclusions</h3><div>We provide a series of recommendations for the treatment of patients with multiple sclerosis who also present with Behçet disease, sarcoidosis, or Sjögren syndrome. Co-presence of any of these rheumatic diseases constitutes a contraindication for some treatments.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100198"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100195
M.L. Martínez Ginés , P. Rojas Lozano
Introduction
The eye is a complex organ that can present complications related to autoimmune diseases, including multiple sclerosis (MS). Ocular manifestations may act as early indicators of autoimmune diseases, and their early diagnosis and treatment are essential to guaranteeing patients' quality of life. This review analyses the main autoimmune eye diseases associated with MS, focusing on intermediate uveitis and its personalised management.
Development
MS-associated uveitis includes various forms of intraocular inflammation affecting different areas of the eye. The relationship between MS and uveitis is complex and involves shared immunological mechanisms and diagnostic and therapeutic challenges. The clinical presentation of uveitis varies from asymptomatic forms to severe vision-threatening complications. The treatment of uveitis involves careful assessment and the consideration of immunomodulatory or immunosuppressive treatment with a view to controlling inflammation and preventing visual sequelae.
Conclusions
Treatment of MS-related uveitis is complex and requires a multidisciplinary approach. Advances in immunomodulatory therapy offer new treatment options, as well as challenges related to adverse reactions and disease management. Further research is needed to better understand the relationship between MS and eye diseases, and to optimise therapeutic strategies and improve patients' visual and neurological outcomes.
{"title":"Autoimmune eye diseases in multiple sclerosis","authors":"M.L. Martínez Ginés , P. Rojas Lozano","doi":"10.1016/j.neurop.2025.100195","DOIUrl":"10.1016/j.neurop.2025.100195","url":null,"abstract":"<div><h3>Introduction</h3><div>The eye is a complex organ that can present complications related to autoimmune diseases, including multiple sclerosis (MS). Ocular manifestations may act as early indicators of autoimmune diseases, and their early diagnosis and treatment are essential to guaranteeing patients' quality of life. This review analyses the main autoimmune eye diseases associated with MS, focusing on intermediate uveitis and its personalised management.</div></div><div><h3>Development</h3><div>MS-associated uveitis includes various forms of intraocular inflammation affecting different areas of the eye. The relationship between MS and uveitis is complex and involves shared immunological mechanisms and diagnostic and therapeutic challenges. The clinical presentation of uveitis varies from asymptomatic forms to severe vision-threatening complications. The treatment of uveitis involves careful assessment and the consideration of immunomodulatory or immunosuppressive treatment with a view to controlling inflammation and preventing visual sequelae.</div></div><div><h3>Conclusions</h3><div>Treatment of MS-related uveitis is complex and requires a multidisciplinary approach. Advances in immunomodulatory therapy offer new treatment options, as well as challenges related to adverse reactions and disease management. Further research is needed to better understand the relationship between MS and eye diseases, and to optimise therapeutic strategies and improve patients' visual and neurological outcomes.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144536222","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100194
A.B. Caminero
{"title":"Management of the most prevalent autoimmune diseases co-occurring with Multiple Sclerosi","authors":"A.B. Caminero","doi":"10.1016/j.neurop.2025.100194","DOIUrl":"10.1016/j.neurop.2025.100194","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100194"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-07-01DOI: 10.1016/j.neurop.2025.100200
M. Roncero Riesco , A. Cabanillas Cabral , Y. El Berdei Montero
Introduction
Autoimmune dermatological diseases have a prevalence greater than 2% in the general population, sometimes as a primary disorder and other times within a context of systemic involvement. Comorbidity with multiple sclerosis (MS) has been described, particularly in the case of psoriasis and bullous pemphigoid, and to a lesser extent in pemphigus vulgaris and other autoimmune skin diseases.
Development
Psoriasis is the autoimmune skin disease for which the most evidence is available on this association, with increased risk in patients with MS. Both disorders probably have common pathophysiological mechanisms. The joint treatment of both diseases will depend on the degree of activity of each one, but in general, it is recommended for patients with MS and psoriasis to avoid interferons, teriflunomide, and anti-CD20 monoclonal antibodies, whereas fumarates and S1P receptor antagonists are recommended. TNF-α inhibitors are formally contraindicated in MS. In the case of bullous pemphigoid, pemphigus vulgaris, and other less common autoimmune dermatological diseases, the relationship with MS is not so clearly established, although an association between the first 2 and neurological diseases, including MS, has been described. Treatment is based on corticotherapy, and classic immunosuppressants or rituximab may be combined, which represent an alternative for joint treatment.
Conclusions
Comorbidity between MS and autoimmune dermatological disorders, and especially psoriasis, requires a joint approach, avoiding treatments that may aggravate one or the other disorders.
{"title":"Autoimmune skin diseases in multiple sclerosis","authors":"M. Roncero Riesco , A. Cabanillas Cabral , Y. El Berdei Montero","doi":"10.1016/j.neurop.2025.100200","DOIUrl":"10.1016/j.neurop.2025.100200","url":null,"abstract":"<div><h3>Introduction</h3><div>Autoimmune dermatological diseases have a prevalence greater than 2% in the general population, sometimes as a primary disorder and other times within a context of systemic involvement. Comorbidity with multiple sclerosis (MS) has been described, particularly in the case of psoriasis and bullous pemphigoid, and to a lesser extent in pemphigus vulgaris and other autoimmune skin diseases.</div></div><div><h3>Development</h3><div>Psoriasis is the autoimmune skin disease for which the most evidence is available on this association, with increased risk in patients with MS. Both disorders probably have common pathophysiological mechanisms. The joint treatment of both diseases will depend on the degree of activity of each one, but in general, it is recommended for patients with MS and psoriasis to avoid interferons, teriflunomide, and anti-CD20 monoclonal antibodies, whereas fumarates and S1P receptor antagonists are recommended. TNF-α inhibitors are formally contraindicated in MS. In the case of bullous pemphigoid, pemphigus vulgaris, and other less common autoimmune dermatological diseases, the relationship with MS is not so clearly established, although an association between the first 2 and neurological diseases, including MS, has been described. Treatment is based on corticotherapy, and classic immunosuppressants or rituximab may be combined, which represent an alternative for joint treatment.</div></div><div><h3>Conclusions</h3><div>Comorbidity between MS and autoimmune dermatological disorders, and especially psoriasis, requires a joint approach, avoiding treatments that may aggravate one or the other disorders.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 3","pages":"Article 100200"},"PeriodicalIF":0.0,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144535783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-19DOI: 10.1016/j.neurop.2025.100203
A. Gutiérrez-Patiño Paúl, E. Aguirre-Siancas
Introduction
The sense of taste is fundamental to life; some studies have revealed a link between dental deafferentation (DD) by upper molar extraction and taste abnormalities in rats. However, no studies have been found that evaluate these variables using the Taste Reactivity Test (TRT).
Methods
Forty male Wistar rats (20 juveniles and 20 adults) were used and assigned to a control and experimental group. Both groups were fitted with cannulae for TRT, while rats in the experimental group also had their right upper molars extracted. Using an ingestive solution (1 M sucrose) and an aversive solution (3 mM denatonium benzoate [BD]), TRT was performed on days 1, 7, 14, and 21. Body and orofacial reactions were recorded and scored.
Results
DD influences ingestive responses in juvenile rats at days 7, 14, and 21; however, it only affects aversive responses at day 21. In adult rats, it influences ingestive responses at days 14 and 21, although it only affects aversive responses at day 14. When comparing ingestive and aversive responses between juvenile and adult rats in the experimental group, differences were identified in ingestive responses at days 7 and 14.
Conclusions
In juvenile and adult rats, upper molar extraction has a negative influence on ingestive and aversive responses. In addition, compared to adult rats, it has a negative effect on ingestive responses in juvenile rats.
{"title":"Taste disorders due to unilateral upper molar extraction in juvenile and adult albino rats","authors":"A. Gutiérrez-Patiño Paúl, E. Aguirre-Siancas","doi":"10.1016/j.neurop.2025.100203","DOIUrl":"10.1016/j.neurop.2025.100203","url":null,"abstract":"<div><h3>Introduction</h3><div>The sense of taste is fundamental to life; some studies have revealed a link between dental deafferentation (DD) by upper molar extraction and taste abnormalities in rats. However, no studies have been found that evaluate these variables using the Taste Reactivity Test (TRT).</div></div><div><h3>Methods</h3><div>Forty male Wistar rats (20 juveniles and 20 adults) were used and assigned to a control and experimental group. Both groups were fitted with cannulae for TRT, while rats in the experimental group also had their right upper molars extracted. Using an ingestive solution (1 M sucrose) and an aversive solution (3 mM denatonium benzoate [BD]), TRT was performed on days 1, 7, 14, and 21. Body and orofacial reactions were recorded and scored.</div></div><div><h3>Results</h3><div>DD influences ingestive responses in juvenile rats at days 7, 14, and 21; however, it only affects aversive responses at day 21. In adult rats, it influences ingestive responses at days 14 and 21, although it only affects aversive responses at day 14. When comparing ingestive and aversive responses between juvenile and adult rats in the experimental group, differences were identified in ingestive responses at days 7 and 14.</div></div><div><h3>Conclusions</h3><div>In juvenile and adult rats, upper molar extraction has a negative influence on ingestive and aversive responses. In addition, compared to adult rats, it has a negative effect on ingestive responses in juvenile rats.</div></div>","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 4","pages":"Article 100203"},"PeriodicalIF":0.0,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-14DOI: 10.1016/j.neurop.2025.100202
E. Martínez-Campos , M. San Miguel , M. Martín Bujanda
{"title":"Cough headache associated with CANVAS: A case report","authors":"E. Martínez-Campos , M. San Miguel , M. Martín Bujanda","doi":"10.1016/j.neurop.2025.100202","DOIUrl":"10.1016/j.neurop.2025.100202","url":null,"abstract":"","PeriodicalId":74283,"journal":{"name":"Neurology perspectives","volume":"5 4","pages":"Article 100202"},"PeriodicalIF":0.0,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144557596","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号